Impact of chronic glucocorticoid treatment on cardiovascular risk profile in patients with systemic lupus erythematosus

Journal of Clinical Rheumatology

Volumn 22, Issue 1, 2016, Pages 8-12

  Moya, Fernando Briceño ^a   Galindo, Luis Francisco Pineda ^a   De La Peña, Maximiliano García ^b  

^a Hospital Especialidades C M La Raza   (Mexico)

^b INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

Author keywords

Cardiovascular risk; Glucocorticoids; SLE

Indexed keywords

AZATHIOPRINE; CHLOROQUINE; CYCLOPHOSPHAMIDE; GLUCOCORTICOID; METHOTREXATE; MYCOPHENOLIC ACID;

ADULT; ARTICLE; CARDIOVASCULAR RISK; COHORT ANALYSIS; CORTICOSTEROID THERAPY; DISEASE COURSE; FEMALE; FRAMINGHAM RISK SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REGISTER; RETROSPECTIVE STUDY; SYSTEMIC LUPUS ERYTHEMATOSUS; ADOLESCENT; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; COMPLICATION; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECTS; FOLLOW UP; IMMUNOLOGY; INCIDENCE; INNATE IMMUNITY; LUPUS ERYTHEMATOSUS, SYSTEMIC; MEXICO; MIDDLE AGED; PROCEDURES; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; TIME FACTOR; YOUNG ADULT;

ADOLESCENT; ADULT; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; IMMUNITY, INNATE; INCIDENCE; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MEXICO; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; YOUNG ADULT;

EID: 84952670035     PISSN: 10761608     EISSN: 15367355     Source Type: Journal    
DOI: 10.1097/RHU.0000000000000335     Document Type: Article

References (30)

1. Urowitz MB, Gladman DD, Abu-Shakra M, et al. Mortality studies in systemic lupus erythematosus. Results from a single center. III. Improved survival over 24 years. J Rheumatol. 1997; 24: 1061-1065.
2. Urowitz MB, Bookman AA, Koehler BE, et al. The bimodal mortality pattern of systemic lupus erythematosus. Am J Med. 1976; 60: 221-225.
3. Manzi S, Selzer F, Sutton-Tyrrell K, et al. Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum. 1999; 42: 51-60.
4. Esdaile JM, Abrahamowicz M, Grodzicky T, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 2001; 44: 2331-2337.
5. Trager J, Ward MM. Mortality and causes of death in systemic lupus erythematosus. Curr Opin Rheumatol. 2001; 13: 345-351.
6. Manzi S, Meilahn EN, Rairie JE, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol. 1997; 145: 408-415.
7. del Rincón ID, Williams K, Stern MP, et al. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum. 2001; 44: 2737-2745.
8. Solomon DH, Karlson EW, Rimm EB, et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation. 2003; 107: 1303-1307.
9. Schiopu E, Au KM, McMahon MA, et al. Prevalence of subclinical atherosclerosis is increased in systemic sclerosis and is associated with serum proteins: a cross-sectional, controlled study of carotid ultrasound. Rheumatology (Oxford). 2014; 53: 704-713.
10. Au K, Singh MK, Bodukam V, et al. Atherosclerosis in systemic sclerosis: a systematic review and meta-analysis. Arthritis Rheum. 2011; 63: 2078-2090.
11. Limaye VS, Lester S, Blumbergs P, et al. Idiopathic inflammatory myositis is associated with a high incidence of hypertension and diabetes mellitus. Int J Rheum Dis. 2010; 13: 132-137.
12. Pasceri P, Yeh ET. A tale of two diseases. Atherosclerosis and rheumatoid arthritis. Circulation. 1999; 100: 2124-2126.
13. Oppenheimer-Marks N, Lipsky PE. Adhesion molecules in rheumatoid arthritis. Springer Semin Immunopathol. 1998; 20: 95-114.
14. Hasunuma Y, Matsuura E, Makita Z, et al. Involvement of beta 2-glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages. Clin Exp Immunol. 1997; 107: 569-573.
15. Lopes-Virella MF, Binzafar N, Rackley S, et al. The uptake of LDL-IC by human macrophages: predominant involvement of the Fc gamma RI receptor. Atherosclerosis. 1997; 135: 161-170.
16. McMahon M, Grossman J, FitzGerald J, et al. Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum. 2006; 54: 2541-2549.
17. Valencia X, Yarboro C, Illei G, et al. Deficient CD4 + CD25high T regulatory cell function in patients with active systemic lupus erythematosus. J Immunol. 2007; 178: 2579-2588.
18. Liu MF, Wang CR, Fung LL, et al. Decreased CD4+ CD25+ T cells in peripheral blood of patients with systemic lupus erythematosus. Scand J Immunol. 2004; 59: 198-202.
19. Wong CK, Lit LC, Tam LS, et al. Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for TH17-mediated inflammation in auto-immunity. Clin Immunol. 2008; 127: 385-393.
20. Eid RE, Rao DA, Zhou J, et al. Interleukin-17 and interferon-gamma are produced concomitantly by human coronary artery-infiltrating T cells and act synergistically on vascular smooth muscle cells. Circulation. 2009; 119: 1424-1432.
21. Aprahamian T, Rifkin I, Bonegio R, et al. Impaired clearance of apoptotic cells promotes synergy between atherogenesis and autoimmune disease. J ExpMed. 2004; 199: 1121-1131.
22. Asai K, Funaki C, Hayashi T, et al. Dexamethasone-induced suppression of aortic atherosclerosis in cholesterol-fed rabbits. Possible mechanisms. Arterioscler Thromb. 1993; 13: 892-899.
23. Tauchi Y, Zushida L, Chono S, et al. Effect of dexamethasone palmitate-low density lipoprotein complex on cholesterol ester accumulation in aorta of atherogenic model mice. Biol Pharm Bull. 2001; 24: 925-929.
24. Cavallero C, Di Tondo U, Mingazzini PL, et al. Cell proliferation in the atherosclerotic plaques of cholesterol-fed rabbits. Part 3. Histological and radioautographic observations on glucocorticoids-treated rabbits. Atherosclerosis. 1976; 25: 145-152.
25. Souverein PC, Berard A, Van Staa TP, et al. Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study. Heart. 2004; 90: 859-865.
26. Doria A, Shoenfeld Y, Wu R, et al. Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. Ann Rheum Dis. 2003; 62: 1071-1077.
27. Doria A, Shoenfeld Y, Pauletto P. Premature coronary disease in systemic lupus. N Engl JMed. 2004; 8: 1571-1575.
28. Ettinger WH Jr, Hazzard WR. Prednisone increases very low density lipoprotein in healthy men. Metabolism. 1988; 37: 1055-1058.
29. Bressler P, De Fronzo RA. Drugs and diabetes. Diabetes Rev. 1994; 2: 53-84.
30. Seguro LP, Rosario C, Shoenfeld Y. Long-term complications of past glucocorticoid use. Autoimmun Rev. 2013; 12: 629-632.